ImmuPharma shares rise on patent milestone and "supportive" study

(Alliance News) - ImmuPharma PLC on Friday announced a "supportive response" to its UK patent application for P140, which was itself supported by "positive" study results.

Shares in ImmuPharma were 10% higher at 5.00 pence on Friday in London.

The London-based specialist drug discovery and development company said it has received a first combined search & examination report, or CSER, in response to its UK patent application for P140, a first-in-class peptide-based therapy for autoimmune and inflammatory diseases.

"The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application," ImmuPharma said.

The company also plans "in due course" to apply for a patent cooperation treaty, with the aim of "seeking protection in key commercial territories".

ImmuPharma also announced the completion of "a new study...[which] was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset."

The study results "were positive and supportive of the patent application," ImmuPharma added.

It said the scientific team is preparing a scientific manuscript on P140, including the recent supporting data, for submission to a peer-reviewed journal.

Additionally, ImmuPharma said it continues to progress discussions with a number of potential partners, including those under signed confidentiality agreements, for P140.

Chief Scientific Officer Sebastien Goudreau said the CSER, combined with the new study results, "represents an important step in strengthening the scientific and intellectual property foundation of the program.

"In parallel, the scientific manuscript now in preparation will help the broader scientific community to understand the unique mechanism of P140 as a precision therapy for patients with Type M immune disorder," he added. "This work reinforces our confidence in P140's potential to become a first‑in‑class, disease‑modifying approach across multiple autoimmune diseases."

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Immupharma